BSC 1401
Alternative Names: BSC-1401Latest Information Update: 06 Jul 2023
At a glance
- Originator BiSiChem
- Class Antineoplastics; Heterocyclic compounds; Small molecules
- Mechanism of Action TGF-beta superfamily protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 31 Oct 2020 BiSiChem signed a technology transfer contract with Therapex for the development of BSC 1401 (BiSiChem pipeline, June 2023)
- 30 Jul 2020 BiSiChem has patent protection for BSC 1401 related TGF-β inhibitors worldwide
- 31 Dec 2019 BiSiChem has a patent pending for BSC 1401 with the USPTO (BiSiChem pipeline, June 2023)